Aug. 6 at 12:25 AM
$APRE has 4m float and 9m marketcap vs
$19 million cash on hand and big upcoming data catalysts + they are looking for expansion of product candidates through combinations with other agents using grant from the National Cancer Institute
- Open-label safety/efficacy data for ATRN-119 expected in the second half of 2025.
- Open-label safety/efficacy data for APR-1051 expected in the second half of 2025.
- The company is evaluating potential expansion opportunities for its product candidates through combinations with other agents, supported by a Phase II SBIR grant from the National Cancer Institute.
- has
$2.56 cash/sh
- last offering was at
$4.46
- has 35% Institutional ownership
- lowest warrants at
$7.29
-As of March 31, 2025, the company had cash and cash equivalents of
$19.3 million, which is insufficient to fund operations for the next twelve months.
